Handelsavisen
prelaunch
Companies Healthcare AMWL.K
AM
AMWL.K NYSE Pharmaceutical Services

American Well Corp

$7,57
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
126,5M USD
P/E
EV / Rev
-0,6x
Div yield
Op margin
-83,4 %
ROE
-13,7 %
Net margin
-79,5 %
Debt / equity
0,00
Beta
52w range
Volume
Day range
Prev close
$8,48
Open
Next earnings
2026-10-28
Ex-dividend
TR 1Y
About

American Well Corp provides digital health services, including virtual care platforms and telehealth solutions, primarily generating revenue through subscription and service fees.

Business. American Well Corp (NYSE: AMWL) is a healthcare services company that operates within the Healthcare Facilities & Services industry. The firm generates revenue through service-based models, focusing on healthcare delivery and related services. American Well is headquartered in the United States and is primarily listed on the New York Stock Exchange under the ticker symbol AMWL. Specific operating segments and geographic breakdowns are not disclosed in the available data.

Classification99 %
SectorHealth Care
Industry groupPharmaceutical Services
Generated · model-assisted
Sell-side consensus
HOLD9 analysts
1 buy8 hold0 sell
Avg 12m price target6,50

Analyst recommendations

9 analysts · consensus Hold
Buy1
Hold8
Sell0
12-month price target
6,50
Consensus of sell-side coverage.
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Hold
9 analysts · indicative
Ownership
Morgan Stanley Smith Barney LLC
largest disclosed fund holder
Profitability
-13,7 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning AMWL.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to AMWL.K. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    American Well Corp (NYSE: AMWL) is a healthcare services company that operates within the Healthcare Facilities & Services industry. The firm generates revenue through service-based models, focusing on healthcare delivery and related services. American Well is headquartered in the United States and is primarily listed on the New York Stock Exchange under the ticker symbol AMWL. Specific operating segments and geographic breakdowns are not disclosed in the available data.

    Classification99 %
    SectorHealth Care
    Industry groupPharmaceutical Services
    AI synthesis
    GENERATED

    American Well operates with a highly liquid capital structure, as evidenced by $276.9 million in cash and equivalents, which significantly exceeds its total liabilities of $143.9 million, resulting in a current ratio of 3.21. The company's price-to-book ratio of 0.36 and price-to-tangible-book ratio of 0.36 indicate that the market values the company at a substantial discount to its book value. Despite this, the company has no long-term debt, which reduces its financial leverage and exposure to interest rate risk.

    Profitability metrics are negative, with a return on equity of -13.72% and a return on assets of -9.83%, both well below industry norms. The company reported a net loss of $49.9 million and an operating loss of $52.4 million, indicating ongoing operational challenges. Gross profit of $23.5 million suggests some margin generation, but it is insufficient to offset operating expenses.

    Geographically and segment-wise, the company's revenue concentration is not disclosed in the available data, but the absence of segment-specific revenue breakdowns implies a lack of diversification. This could pose a risk if demand in its primary market or service line declines.

    The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the available data. However, the negative operating and free cash flows of -$81.5 million and -$46.8 million, respectively, suggest that the company is not generating sufficient cash to fund operations or expansion. The capital expenditure of -$8.1 million indicates some investment in infrastructure, but it is minimal relative to the company's overall financial position.

    Risk factors include the company's negative net income and operating income, which could affect its ability to sustain operations without external financing. The risk assessment indicates low liquidity and dilution risk, but the absence of long-term debt does not eliminate the need for ongoing cash flow management. No immediate filing-based liquidity or dilution flags were detected, but the company's financial performance suggests a need for continued monitoring.

    Recent events, including analyst estimates, show a mean price target of $6.50 and a median of $5.50, with a mean recommendation of 2.89, indicating a generally cautious outlook. The lack of strong buy ratings and the presence of eight hold ratings suggest that analysts are not optimistic about the company's near-term prospects.

    Key takeaways
    • American Well has a highly liquid balance sheet with $276.9 million in cash and equivalents, but it is not generating positive operating cash flow.
    • The company's profitability metrics are negative, with a return on equity of -13.72% and a return on assets of -9.83%.
    • The company's market valuation is significantly below book value, as indicated by a price-to-book ratio of 0.36.
    • Analysts have a generally cautious outlook, with a mean price target of $6.50 and a mean recommendation of 2.89.
    • The company's financial performance suggests a need for continued monitoring of liquidity and operational efficiency.

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 5

    Free cash flow improved by 69.1% year-over-year to -$59.3 million in FY2026, signaling significant operational efficiency gains.

    The company maintains a zero long-term debt position, providing a strong balance sheet with no interest obligations.

    Gross profit increased to $134.1 million in FY2026, demonstrating an ability to generate top-line margin despite revenue declines.

    Net income losses narrowed by 54.0% year-over-year to -$95.7 million in FY2026, indicating a clear path toward profitability.

    Cash conversion ratio of 1.63 exceeds the healthcare facilities cohort median of 1.36, suggesting superior cash management.

    BEAR CASE · 3

    Revenue declined 0.3% annually over four years, falling to $249.3 million in FY2026, indicating persistent top-line stagnation.

    Return on equity of -13.7% ranks in the bottom quartile, reflecting poor capital efficiency compared to peers.

    The company carries a high credit risk flag, suggesting potential difficulties in securing favorable financing terms.

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2026-05-05
    Q1 2026 · Quarter highlights
    Open report →

    Revenue $54.9M, −17,9% YoY.

    Revenue$54.9M−17,9 % YoY
    Operating income
    Net income
    Free cash flow
    EPS
    Operating cash flow-$983.0k+96,1 % YoY
    Financials
    Income statement
    Revenue$54.9M
    Gross profit
    Operating income
    Net income
    Balance sheet
    Total assets
    Total liabilities$98.6M
    Total equity$227.3M
    Cash & equivalents$179.2M
    Long-term debt
    Cash flow
    Operating cash flow-$983.0k
    CapEx-$2.8M
    Free cash flow
    SBC
    Highlights
    • Revenue $54.9M, −17,9% YoY

    Valuation TTM

    Market price
    $7,57
    Market cap
    $130.0M
    Enterprise value
    -$146.9M
    P/E
    Non-GAAP P/E
    EV / Revenue
    -0.6x
    EV / Op income
    EV / OCF
    P / B
    0.4x
    P / Tangible book
    0.4x
    Tangible book
    $363.9M
    Net cash
    $276.9M
    Current ratio
    3.2
    Debt / equity
    0.0
    ROA
    -9.8%
    ROE
    -13.7%
    Cash conversion
    163.0%
    CapEx / revenue
    -12.9%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    INDUSTRYSEGMENTCOMPANYHealthcareIndustryPharmaceutical Services41,1B node revenuePHG 49,5%EHC 14,5%BKD 7,8%TDOC 6,2%HIMS 5,7%NTRA 5,6%NHC 3,7%PNTG 2,3%Other 4,8%
    Source: company disclosures · own-taxonomy revenue-covered setAMWL 0,6% · rank #12 of 18

    Business relationships

    Business relationships3 disclosed relationships · 1 type · extracted from filings & disclosures
    Customers3
    ANON:CUST:AMWL.K:P22ANON:CUST:AMWL.K:P22Customer88%Source ↗
    ANON:CUST:AMWL.K:P31ANON:CUST:AMWL.K:P31Customer88%Source ↗

    Supply chain

    Vendors → AMWL ↔ Partners → Customers · click any node to drill
    VENDORSPARTNERSCUSTOMERSAMWLAMWLAmerican Well Corp3 entitiesANON:CUST:AMWL.K:P22ANON:CUST:AMWL.K:P31Elevance Health IncHealthcare Services & EqUS
    3 mentions in 10-K0 from corporate websites0 from news dispatches
    Updated 2026-07-04

    Peer comparison

    Peer comparison8 peers · vs AMWL · multiples and returns
    PH
    PHG
    PHG.BK
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    EH
    EHC
    Encompass Health Corp
    $112,47
    11,5B USD
    P/E
    18,6x
    vs self
    Div yield
    0,6 %
    vs self
    ROE
    23,2 %
    +36,9 vs self
    BK
    BKD
    Brookdale Senior Living Inc
    $14,37
    3,4B USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    469,6 %
    +483,4 vs self
    TD
    TDOC
    TELADOC HEALTH, INC.
    $6,57
    1,2B USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    -14,5 %
    -0,7 vs self
    HI
    HIMS
    Hims & Hers Health Inc
    $25,20
    5,8B USD
    P/E
    48,1x
    vs self
    Div yield
    vs self
    ROE
    23,7 %
    +37,5 vs self
    NT
    NTRA
    NATERA, INC.
    $270,36
    38,6B USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    -8,5 %
    +5,2 vs self
    NH
    NHC
    National Healthcare Corp
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    PN
    PNTG
    Pennant Group Inc
    $40,18
    1,4B USD
    P/E
    39,2x
    vs self
    Div yield
    vs self
    ROE
    8,1 %
    +21,8 vs self

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    -4,24
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    9
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-16 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate-4,24
    Revenueno estimateno estimate199,4M USD
    Operating incomeno estimateno estimate-73,1M USD
    Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution9 analysts
    Strong buy0
    Buy1
    Hold8
    Sell0
    Strong sell0
    12-month price target$6,50 · Median $5,50
    Low $5,00High $9,00
    Operating income · consensus-73,1M USD
    EPS surprise
    −40,7 %
    reported vs consensus · miss
    Revenue surprise
    +25,1 %
    reported vs consensus · beat

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$5,00
    Mean$6,50
    Median$5,50
    High$9,00
    Spot$7,57
    −14.1 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin-83,4 %Bottom quartile
    Net Margin-79,5 %Bottom quartile
    ROE-13,7 %Below median
    Capex / Rev-12,9 %Bottom quartile
    D/E0,00Above median
    Cash Conv1,63Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Return On Equity
      net_income / total_equity
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    • Ev To Revenue
      enterprise_value / revenue
    Source documents
    • American Well Corp Market data — financials · 2026-05-27
    • American Well Corp Market data — analyst estimates · 2026-05-27
    • American Well Corp Market data — ESG · 2026-05-27

    Ownership & reference

    Top holders

    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$6M
    • Dimensional Fund Advisors, L.P.Investment Managers · as of 2026-03-310,00 %$0M
    • Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$1M
    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$1M
    • BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$2M
    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$3M
    • Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$0M
    • T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$0M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M
    • PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M

    Insider activity

    Net selling1 buys · 14 sellsnet -$412K11 insiders · last 365d
    • Goldwasser RivkaDirector · Class A Common StockOther 14 501 · 2026-06-16
    • Schlegel Stephen J.Director · Class A Common StockOther 14 501 · 2026-06-16
    • Jackson Deborah CDirector · Class A Common StockOther 14 501 · 2026-06-16
    • Cosgrove Delos M.Director · Class A Common StockOther 14 501 · 2026-06-16
    • Webb Robert ThomasDirector · Class A Common StockOther 14 501 · 2026-06-16
    • Ross DerekDirector · Class A Common StockOther 14 501 · 2026-06-16
    • Schlegel Stephen J.Director · Class A Common StockSold 9 750 @ $8,76$85K · 2026-06-11
    • HIRSCHHORN MARKChief Financial Officer · Class A Common StockSold 10 761 @ $9,74$105K · 2026-06-01
    • McNeice Paul FrancisChief Accounting Officer · Class A Common StockSold 112 @ $9,74$1K · 2026-06-01
    • Gotlib PhyllisPresident, International · Class A Common StockSold 3 573 @ $9,74$35K · 2026-06-01
    • Schoenberg IdoDirector, Chairman, co-CEO · Class A Common StockBought 670 @ $7,37$5K · 2026-05-07
    • McNeice Paul FrancisChief Accounting Officer · Class A Common StockSold 383 @ $5,30$2K · 2026-04-01
    • Zamansky DmitryChief Product & Tech. Officer · Class A Common StockSold 5 575 @ $5,30$30K · 2026-04-01
    • Gotlib PhyllisPresident, International · Class A Common StockSold 3 706 @ $5,30$20K · 2026-04-01
    • Zamansky DmitryChief Product & Tech. Officer · Class A Common StockOther 50 413 · 2026-03-04
    • McNeice Paul FrancisChief Accounting Officer · Class A Common StockOther 8 066 · 2026-03-04
    • HIRSCHHORN MARKChief Financial Officer · Class A Common StockOther 50 413 · 2026-03-04
    • Gotlib PhyllisPresident, International · Class A Common StockOther 50 413 · 2026-03-04
    • HIRSCHHORN MARKChief Financial Officer · Class A Common StockSold 10 796 @ $5,24$57K · 2026-03-02
    • Zamansky DmitryChief Product & Tech. Officer · Class A Common StockSold 2 472 @ $5,45$13K · 2026-03-02
    • Gotlib PhyllisPresident, International · Class A Common StockSold 3 573 @ $5,24$19K · 2026-03-02
    • McNeice Paul FrancisChief Accounting Officer · Class A Common StockSold 130 @ $5,24$681 · 2026-03-02
    • Zamansky DmitryChief Product & Tech. Officer · Class A Common StockSold 6 243 @ $4,85$30K · 2026-01-02
    • McNeice Paul FrancisChief Accounting Officer · Class A Common StockSold 384 @ $4,85$2K · 2026-01-02
    • Gotlib PhyllisPresident, International · Class A Common StockSold 3 707 @ $4,85$18K · 2026-01-02

    Short positioning

    188.3Kshares short+7.2% vs prior
    1.28days to cover
    52.1%short of daily vol
    19fails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    AMWL.KCanonical
    NYSE · USD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.
    Relationship graph
    AMWLANON:CUSANON:CUSELV.OPharmaceutical
    This companySectorCustomers

    Evidence & claims

    From filings & derived data
    • Capex (YoY) (2025-12-31 vs 2024-12-31): -82.4%Derived (calculated)
    • Net margin (FY 2025-12-31): -38.4%Derived (calculated)
    • Return on equity (FY 2025-12-31): -40.6%Derived (calculated)
    • Return on assets (FY 2025-12-31): -29.6%Derived (calculated)
    • Current ratio (FY 2025-12-31): 3.37xDerived (calculated)
    • Debt-to-equity (FY 2025-12-31): 0.32xDerived (calculated)
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -20.1%Derived (calculated)
    • EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 57.1%Derived (calculated)
    • EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 57.1%Derived (calculated)
    • Net income (YoY) (2025-12-31 vs 2024-12-31): 54.0%Derived (calculated)
    • Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 48.2%Derived (calculated)
    • Operating income (YoY) (2025-12-31 vs 2024-12-31): 51.6%Derived (calculated)
    • R&D expense (YoY) (2025-12-31 vs 2024-12-31): -15.3%Derived (calculated)
    • Revenue (YoY) (2025-12-31 vs 2024-12-31): -2.0%Derived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -22.7%Derived (calculated)
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): -25.7%Derived (calculated)
    • Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -36.5%Derived (calculated)
    • Cash & equivalents (annual): USD 182.33MSEC XBRL filing
    • Shareholders' equity (annual): USD 235.58MSEC XBRL filing
    • Pre-tax income (annual): USD -94.53MSEC XBRL filing
    • Capex (annual): USD 21KSEC XBRL filing
    • Net income (annual): USD -95.7MSEC XBRL filing
    • Current assets (annual): USD 246.68MSEC XBRL filing
    • EPS (basic) (annual): USD-PER-SHARES -6SEC XBRL filing
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-08-04 00:00 UTCTRANSCRIPTEarnings call — Q3 2026
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: insider_flow_signal (90d)
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-16 00:00 UTCINSIDER10 insider transactions — 2026-06 · net sell $226k
    2026-06-16INSIDERGoldwasser Rivka transacted 14.5k sh Class A Common Stock — Director
    2026-06-16INSIDERSchlegel Stephen J. transacted 14.5k sh Class A Common Stock — Director
    2026-06-16INSIDERJackson Deborah C transacted 14.5k sh Class A Common Stock — Director
    2026-06-16INSIDERCosgrove Delos M. transacted 14.5k sh Class A Common Stock — Director
    2026-06-16INSIDERWebb Robert Thomas transacted 14.5k sh Class A Common Stock — Director
    2026-06-16INSIDERRoss Derek transacted 14.5k sh Class A Common Stock — Director
    2026-06-11INSIDERSchlegel Stephen J. sold 9.8k sh Class A Common Stock — Director ~$85k
    2026-06-01INSIDERHIRSCHHORN MARK sold 10.8k sh Class A Common Stock — Chief Financial Officer ~$105k
    2026-06-01INSIDERMcNeice Paul Francis sold 112 sh Class A Common Stock — Chief Accounting Officer ~$1k
    2026-06-01INSIDERGotlib Phyllis sold 3.6k sh Class A Common Stock — President, International ~$35k
    2026-05-12FILING8-K filing →
    2026-05-07 00:00 UTCINSIDER1 insider transaction — 2026-05
    2026-05-07INSIDERSchoenberg Ido bought 670 sh Class A Common Stock — Director, Chairman, co-CEO ~$5k
    2026-05-05 16:05 UTCEARNINGSQuarterly results — Q1 2026 Revenue USD 54.9M
    2026-05-05FILING10-Q filing →
    2026-05-05FILING8-K filing →
    2026-04-23FILINGDEF 14A filing →
    2026-04-02FILING8-K filing →
    2026-04-01 00:00 UTCINSIDER3 insider transactions — 2026-04
    2026-04-01INSIDERMcNeice Paul Francis sold 383 sh Class A Common Stock — Chief Accounting Officer ~$2k
    2026-04-01INSIDERZamansky Dmitry sold 5.6k sh Class A Common Stock — Chief Product & Tech. Officer ~$30k
    2026-04-01INSIDERGotlib Phyllis sold 3.7k sh Class A Common Stock — President, International ~$20k
    2026-03-04 00:00 UTCINSIDER8 insider transactions — 2026-03
    2026-03-04INSIDERZamansky Dmitry transacted 50.4k sh Class A Common Stock — Chief Product & Tech. Officer
    2026-03-04INSIDERMcNeice Paul Francis transacted 8.1k sh Class A Common Stock — Chief Accounting Officer
    2026-03-04INSIDERHIRSCHHORN MARK transacted 50.4k sh Class A Common Stock — Chief Financial Officer
    2026-03-04INSIDERGotlib Phyllis transacted 50.4k sh Class A Common Stock — President, International
    2026-03-02INSIDERHIRSCHHORN MARK sold 10.8k sh Class A Common Stock — Chief Financial Officer ~$57k
    2026-03-02INSIDERZamansky Dmitry sold 2.5k sh Class A Common Stock — Chief Product & Tech. Officer ~$13k
    2026-03-02INSIDERGotlib Phyllis sold 3.6k sh Class A Common Stock — President, International ~$19k
    2026-03-02INSIDERMcNeice Paul Francis sold 130 sh Class A Common Stock — Chief Accounting Officer ~$1k
    2026-02-12 16:19 UTCEARNINGSQuarterly results — Q4 2025 Revenue USD 55.3M · Net USD -24.9M
    2026-02-12 16:19 UTCEARNINGSAnnual results — FY 2026 Revenue USD 249.3M · Net USD -95.7M
    2026-02-12FILING10-K filing →
    2026-02-12FILING8-K filing →
    Showing the 40 most recent of 59 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage